Recombinant Human ADAM9 Protein, CF

Catalog # Availability Size / Price Qty
939-AD-020
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (10)
FAQs
Supplemental Products
Reviews (1)

Recombinant Human ADAM9 Protein, CF Summary

Product Specifications

Purity
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2 (Catalog # ES003). The specific activity is >1.0 pmol/min/µg, as measured under the described conditions.
Source
Mouse myeloma cell line, NS0-derived human ADAM9 protein
Ala206-Asp697, with a C-terminal 10-His tag
Accession #
N-terminal Sequence
Analysis
Ala206
Structure / Form
Mature form
Predicted Molecular Mass
55 kDa
SDS-PAGE
64 kDa, reducing conditions

Product Datasheets

You must select a language.

x

939-AD

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

939-AD

Formulation Supplied as a 0.2 μm filtered solution in MES and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Assay Procedure

Materials
  • Assay Buffer: 25 mM Tris, 2.5 µM ZnCl2, 0.005% (w/v) Brij-35, pH 9.0
  • Recombinant Human ADAM-9 (rhADAM9) (Catalog # 939-AD)
  • Fluorogenic Peptide Substrate III: MCA-Pro-Leu-Ala-Gln-Ala-Val-DPA-Arg-Ser-Ser-Ser-Arg-NH2 (Catalog # ES003)
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
  1. Dilute rhADAM9 to 40 µg/mL in Assay Buffer.
  2. Dilute substrate to 20 µM in Assay Buffer.
  3. Combine equal volumes of 40 µg/mL rhADAM9 and 20 µM substrate. Include a control containing Assay Buffer and 20 µM substrate without any rhADAM9.
  4. Incubate reactions at 37 °C for 30 minutes.
  5. Load 100 μL of reactions and control per well in a black plate.
  6. Read with excitation and emission wavelengths of 320 nm and 405 nm (top read), respectively, in endpoint mode.
  7. Calculate specific activity:

     Specific Activity (pmol/min/µg) =

Adjusted Fluorescence* (RFU) x Conversion Factor** (pmol/RFU)
Incubation time (min) x amount of enzyme (µg)

     *Adjusted for Control
     **Derived using calibration standard MCA-Pro-Leu-OH (Bachem, Catalog # M-1975).

Per Well:
  • rhADAM9: 2.0 µg
  • Substrate: 10 µM
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: ADAM9

ADAM9, also known as MDC9 or meltrin gamma, is a member of the ADAM family that contains a disintegrin and metalloprotease‑like domain (1). Like other membrane-anchored ADAMs, ADAM9 consists of a pro domain with a cysteine switch and furin cleavage sequence, a catalytic domain with the zinc‑binding site and Met-turn expected for reprolysins, a disintegrin-like domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and the cytoplasmic domain. ADAM9 is able to cleave peptides corresponding to cleavage sites of tumor necrosis factor-alpha (TNF-alpha ), the p75 TNF receptor, the beta -amyloid protein precursor, and the c‑kit ligand-1, implying that it may participate in shedding of these membrane proteins (2). In fact, ADAM9 has been shown to shed membrane‑anchored heparin-binding EGF-like growth factor (3). In addition, it also cleaves oxidized insulin beta -chain and fibronectin (2,4). Besides its catalytic activity, ADAM9 functions as an adhesion molecule through binding of its disintegrin domain to integrins such as alpha v beta 5 and alpha 6 beta 1 (5, 6). The cytoplasmic domain of ADAM9 interacts with Src homology 3
(SH3)‑containing proteins and protein kinase C, and may mediate different signaling pathways (3, 7). ADAM9 is widely expressed in tissues (8).

References
  1. Moss, et al. (2001) DDT 6:417.
  2. Roghan, et al. (1999) J. Biol. Chem. 274:3531.
  3. Izumi, et al. (1998) EMBO J. 17:7260.
  4. Schwettmann and Tschesche (2001) Prot. Expre. & Purif. 21:65.
  5. Nath, et al. (2000) J. Cell Sci. 113:2319.
  6. Zhou, et al. (2001) Biochem. Biophys. Res. Comm. 280:574.
  7. Howard, et al. (1999) J. Biol. Chem. 274:31693.
  8. Weskamp, et al. (1996) J. Cell. Biol. 132:717.
Long Name
A Disintegrin and Metalloprotease-like Domain 9
Entrez Gene IDs
8754 (Human); 11502 (Mouse)
Alternate Names
a disintegrin and metalloproteinase domain 9 (meltrin gamma); ADAM 9; ADAM metallopeptidase domain 9 (meltrin gamma); ADAM metallopeptidase domain 9; ADAM9; Cellular disintegrin-related protein; cone rod dystrophy 9; CORD9; disintegrin and metalloproteinase domain-containing protein 9; EC 3.4.24; EC 3.4.24.-; MCMP; MCMPMDC9KIAA0021Mltng; MDC9; Meltrin gamma; Meltrin-gamma; Metalloprotease/disintegrin/cysteine-rich protein 9; MLTNG; Myeloma cell metalloproteinase

Citations for Recombinant Human ADAM9 Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

10 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors
    Authors: JA Scribner, SW Hicks, KW Sinkeviciu, NC Yoder, G Diedrich, JG Brown, J Lucas, ME Fuller, T Son, A Dastur, J Hooley, CW Espelin, M Themeles, FZ Chen, Y Li, M Chiechi, J Lee, B Barat, L Widjaja, S Gorlatov, J Tamura, V Ciccarone, O Ab, KA McEachem, S Koenig, EH Westin, PA Moore, T Chittenden, RJ Gregory, E Bonvini, D Loo
    Molecular Cancer Therapeutics, 2022-07-05;0(0):.
    Species: Human
    Sample Types: Recombinant Proteins
    Applications: ELISA Capture
  2. The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer
    Authors: TT Le, CL Hsieh, IH Lin, CY Chu, AD Do, SH Chen, K Shigemura, K Kitagawa, M Fujisawa, MC Liu, KC Chen, SY Sung
    American journal of cancer research, 2022-01-15;12(1):176-197.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10
    Authors: K Goto, J Arai, A Stephanou, N Kato
    Oncotarget, 2018-04-10;9(27):18821-18831.
    Applications: Enzyme Assay
  4. Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis
    Authors: N Giebeler, A Schönefu beta, J Landsberg, T Tüting, C Mauch, P Zigrino
    Oncogene, 2017-05-29;0(0):.
    Applications: Enzyme Assay
  5. ADAM8 as a drug target in pancreatic cancer.
    Authors: Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia A, Hofling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem R, Moss M, Rasmussen F, Miller M, Lauffenburger D, Tuveson D, Nimsky C, Bartsch J
    Nat Commun, 2015-01-28;6(0):6175.
    Species: Primate - Chlorocebus aethiops (African Green Monkey)
    Sample Types: Whole Cells
  6. ADAM9 is a novel product of polymorphonuclear neutrophils: regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury.
    Authors: Roychaudhuri R, Hergrueter A, Polverino F, Laucho-Contreras M, Gupta K, Borregaard N, Owen C
    J Immunol, 2014-07-25;193(5):2469-82.
    Species: Human
    Sample Types: Protein, Whole Cells
    Applications: Bioassay, Enzyme Assay
  7. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
    Authors: Moss ML, Bomar M, Liu Q, Sage H, Dempsey P, Lenhart PM, Gillispie PA, Stoeck A, Wildeboer D, Bartsch JW, Palmisano R, Zhou P
    J. Biol. Chem., 2007-09-25;282(49):35712-21.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  8. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
    Authors: Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA
    Cancer Cell, 2006-07-01;10(1):39-50.
    Species: Human
    Sample Types:
    Applications: Enzyme Assay
  9. ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin.
    Authors: Karadag A, Zhou M, Croucher PI
    Blood, 2005-12-22;107(8):3271-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency.
    Authors: Hinkle CL, Sunnarborg SW, Loiselle D, Parker CE, Stevenson M, Russell WE, Lee DC
    J. Biol. Chem., 2004-04-05;279(23):24179-88.
    Species: Mouse
    Sample Types: Recombinant Protein
    Applications: Enzyme Assay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human ADAM9 Protein, CF

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human ADAM9 Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human ADAM9 Protein, CF
By Anonymous on 05/07/2017
Application: In vitro bioactivity in cell culture